Enlivex Receives Regulatory Authorization to Expand its Phase II Sepsis Trial into Greece

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that, following a review of the ...

READ THE ORIGINAL POST AT stockhouse.com